CNS-targeting pharmacological interventions for the metabolic syndrome
Kerstin Stemmer,1,2 Timo D. Müller,1,2 Richard D. DiMarchi,3 Paul T. Pfluger,1,2 and Matthias H. Tschöp1,2,4
1Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.
2German Center for Diabetes Research (DZD), Neuherberg, Germany.
3Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
4Division of Metabolic Diseases, Department of Medicine, Technische Universität München, Munich, Germany.
Address correspondence to: Kerstin Stemmer, Institute for Diabetes and Obesity, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany. Phone: 49.89.3187.2109; Email: kerstin.stemmer@helmholtz-muenchen.de.
Find articles by Stemmer, K. in: JCI | PubMed | Google Scholar
1Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.
2German Center for Diabetes Research (DZD), Neuherberg, Germany.
3Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
4Division of Metabolic Diseases, Department of Medicine, Technische Universität München, Munich, Germany.
Address correspondence to: Kerstin Stemmer, Institute for Diabetes and Obesity, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany. Phone: 49.89.3187.2109; Email: kerstin.stemmer@helmholtz-muenchen.de.
Find articles by Müller, T. in: JCI | PubMed | Google Scholar
1Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.
2German Center for Diabetes Research (DZD), Neuherberg, Germany.
3Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
4Division of Metabolic Diseases, Department of Medicine, Technische Universität München, Munich, Germany.
Address correspondence to: Kerstin Stemmer, Institute for Diabetes and Obesity, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany. Phone: 49.89.3187.2109; Email: kerstin.stemmer@helmholtz-muenchen.de.
Find articles by DiMarchi, R. in: JCI | PubMed | Google Scholar
1Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.
2German Center for Diabetes Research (DZD), Neuherberg, Germany.
3Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
4Division of Metabolic Diseases, Department of Medicine, Technische Universität München, Munich, Germany.
Address correspondence to: Kerstin Stemmer, Institute for Diabetes and Obesity, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany. Phone: 49.89.3187.2109; Email: kerstin.stemmer@helmholtz-muenchen.de.
Find articles by
Pfluger, P.
in:
JCI
|
PubMed
|
Google Scholar
|
1Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.
2German Center for Diabetes Research (DZD), Neuherberg, Germany.
3Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
4Division of Metabolic Diseases, Department of Medicine, Technische Universität München, Munich, Germany.
Address correspondence to: Kerstin Stemmer, Institute for Diabetes and Obesity, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany. Phone: 49.89.3187.2109; Email: kerstin.stemmer@helmholtz-muenchen.de.
Find articles by Tschöp, M. in: JCI | PubMed | Google Scholar
First published August 5, 2019 - More info
J Clin Invest. 2019;129(10):4058–4071. https://doi.org/10.1172/JCI129195.
© 2019 American Society for Clinical Investigation
The metabolic syndrome (MetS) encompasses medical conditions such as obesity, hyperglycemia, high blood pressure, and dyslipidemia that are major drivers for the ever-increasing prevalence of type 2 diabetes, cardiovascular diseases, and certain types of cancer. At the core of clinical strategies against the MetS is weight loss, induced by bariatric surgery, lifestyle changes based on calorie reduction and exercise, or pharmacology. This Review summarizes the past, current, and future efforts of targeting the MetS by pharmacological agents. Major emphasis is given to drugs that target the CNS as a key denominator for obesity and its comorbid sequelae.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
- Print subscription
- $830
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)